Promed Bioscience signs MoU with RSL Revolutionary Labs Ltd to supply collagen for RSL’s specialty skincare products

17 June 2020

Promed Bioscience signs a Memorandum of Understanding with RSL Revolutionary Labs Ltd for the joint development of collagen based skincare products that are designed specifically for oncology patients.

Cancer patients undergoing chemotherapy, immunotherapy or radiation treatment face serious dermatological issues, while current market solutions are usually ineffective, offering more of a cosmetic rather than a therapeutic effect. Promed’s soluble 3D atelocollagen, combined with RSL’s proprietary blend of herbal extracts, will result in a new class of medical-grade skincare products to address therapy side effects, improving quality of life and ensuring that patients can continue their life-saving treatments.